Incyte’s product portfolio
Incyte’s (INCY) product portfolio includes targeted therapies and immunotherapies for oncology as well as non-oncology products. Incyte currently markets only two products: Jakafi and Iclusig. Another product, Olumiant (Baricitinib), has recently been approved in Japanese markets for rheumatoid arthritis.
The marketing rights for Jakafi outside of US markets are with Novartis (NVS), which markets the drug as Jakavi. The worldwide rights for development and commercialization of Olumiant are licensed to Eli Lilly (LLY).
Incyte has classified its oncology product portfolio into two categories based on the method of treatment used to cure the disease:
- targeted anti-cancer therapies
- immuno-oncology or immunotherapies
Targeted anti-cancer therapies include drugs that target cancer cells while causing low damage to normal cells. Targeted therapies in Incyte’s portfolio include Jakafi (ruxolitinib) and capmatinib.
Immunotherapies are drugs that target a patient’s immune system to fight cancer cells. Incyte’s immunotherapy portfolio includes Epacadostat. Notably, Incyte has entered into collaborations with Merck (MRK) and Bristol-Myers Squibb (BMY) for the development of Epacadostat.
Incyte acquired Iclusig from Ariad Pharmaceuticals (ARIA) in June 2016. Iclusig is used to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia.
Incyte’s non-oncology portfolio includes two drugs: Baricitinib and Ruxolitinib.
Eli Lilly (LLY) holds the exclusive worldwide rights for the development and commercialization of Olumiant (baricitinib). The European Commission approved the marketing authorization application for Olumiant (baricitinib) in February 2017, while the Japan Ministry of Health, Labor, and Welfare granted marketing approval for Olumiant 2 mg and 4 mg tablets for the treatment of rheumatoid arthritis on July 3, 2017. However, the FDA (US Food and Drugs Administration) has declined the new drug application for Olumiant in its current form.
Eli Lilly and Incyte have also entered into an agreement for development and commercialization of Ruxolitinib for the treatment of graft-versus-host disease in US markets. For outside of US markets, Ruxolitinib is licensed to Novartis (NVS).
To divest company-specific risks, investors can consider ETFs like the Vanguard Healthcare ETF (VHT), which has 0.6% of its total assets in Incyte. VHT also has 2.2% in Eli Lilly, 5.6% in Pfizer (PFE), and 3.2% in AbbVie (ABBV).
Incyte (INCY) distributes its key drug, Jakafi, through its own network of specialty pharmacy providers and wholesalers in US markets.
Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.
The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.
Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.
Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.
As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.
Amazon is discontinuing its Amazon Restaurants service, which has been delivering food for restaurants in parts of the United States. Amazon Restaurants launched in the United States in 2015 and entered the British market the following year. However, it met strong opposition in the British market.